中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (9): 693-697.doi: 10.12144/zgmfskin202309693

• 综述 • 上一篇    下一篇

Deucravacitinib治疗银屑病研究进展

原晋湘1,王甜雪2,张峻岭2   

  1. 1天津中医药大学研究生院，天津，301617；2天津市中医药研究院附属医院皮肤科，天津，300120
  • 出版日期:2023-09-15 发布日期:2023-09-05

Research progress of deucravacitinib in the treatment of psoriasis

YUAN Jinxiang1, WANG Tianxue2, ZHANG Junling2   

  1. 1 Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; 2 Dermatological Department, Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine, Tianjin 300120, China
  • Online:2023-09-15 Published:2023-09-05

PDF (PC)

48

摘要： 银屑病是由遗传和环境共同诱发、免疫介导的慢性炎症性皮肤病。酪氨酸激酶2（TYK2）和信号传导及转录激活蛋白（STAT）是细胞因子调节的主要信号通路，在介导炎症和免疫反应中至关重要。Deucravacitinib是被美国食品药品监督管理局(FDA)唯一获批的TYK2抑制剂，该药是用于治疗中重度银屑病的首个创新药物，其通过TYK2/STAT通路介导关键炎症介质的转录参与银屑病的治疗。相较于其他酪氨酸蛋白激酶（JAK）抑制剂，Deucravacitinib通过变构抑制以其高选择性抑制炎症通路的特点具有更大前景。本文总结了Deucravacitinib在银屑病治疗中的作用机制及研究进展。

关键词: Deucravacitinib；TYK2抑制剂；银屑病, 变构抑制

Abstract: Psoriasis is a chronic inflammatory skin disease induced by a combination of genetics and environment and mediated by immunity. Tyrosine kinase 2 (TYK2) and Signal Transducer and Activator of Transcription (STAT) protein are the main pathways of cytokine regulation and play critical roles in mediating inflammation and immune response. Deucravacitinib is the first innovative drug recently approved by the U.S. Food and Drug Administration (FDA) as the only TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. It mediates the transcription of key inflammatory mediators through the TYK2/STAT pathway and in the pathogenesis of psoriasis. Compared with other Janus Kinase (JAK) inhibitors, deucravacitinib is more promising for its highly selective inhibition of inflammatory pathways through metabotropic inhibition. This paper summarizes the mechanism of action and research progress of deucravacitinib in the treatment of psoriasis.

Key words: deucravacitinib, TYK2 inhibitors, psoriasis, allosteric inhibition